Lei Huo, MD, PhD

Peer-Reviewed Articles

1. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen H. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer 23(4):415-422, 2023. e-Pub 2023. PMID: 36878823.
2. Kono M, Fujii T, Lyons GR, Huo L, Bassett R, Gong Y, Karuturi MS, Tripathy D, Ueno NT. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Res Treat 160(1):101-109, 2016. e-Pub 2016. PMID: 27663436.
3. Vila J, Mittendorf EA, Basset RL, Bedrosian I, Shaitelman SF, Stauder MC, Chavez-McGregor M, Litton JF, Yang WT, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast cancer patients. Ann Surg Oncol 23(11):3501-3509, 2016. e-Pub 2016. PMID: 27216742.
4. He H, Plaxco JS, Wei W, Huo L, Candelaria RP, Kuerer HM, Yang WT. Incremental cancer detection using breast ultrasonography versus breast magnetic resonance imaging in the evaluation of newly diagnosed breast cancer patients. Br J Radiol 89(1065):1065, 2016. e-Pub 2016. PMID: 27384241.
5. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA. miR-141-Mediated regulation of brain metastasis from breast cancer. J Natl Cancer Inst 108(8), 2016. e-Pub 2016. PMID: 27075851.
6. Wolfe AR, Bambhroliya A, Reddy JP, Debeb BG, Huo L, Larson R, Li L, Ueno NT, Woodward WA. MiR-33a Decreases high-density lipoprotein-induced radiation sensitivity in breast cancer. Int J Radiat Oncol Biol Phys 95(2):791-9, 2016. e-Pub 2016. PMID: 27055396.
7. Huo L (corresponding author), Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol 29(4):330-46, 2016. e-Pub 2016. PMID: 26916073.
8. Liao Q, Liu W, Liu Y, Wang F, Wang C, Zhang J, Chu M, Jiang D, Xiao L, Shao W,Sheng Z, Tao X, Huo L, Yin CC, Zhang Y, Lee G, Huang J, Li Z, Qiu X. Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis. Oncotarget 24(6):40081-94, 2015. PMID: 26472025.
9. Huo L (corresponding author), Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology 67(2):245-54, 2015. e-Pub 2015. PMID: 25564996.
10. Adrada BE, Huo L, Lane DL, Arribas EM, Resetkova E, Yang W. Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 22(4):1111-7, 2015. e-Pub 2014. PMID: 25287438.
11. Guo M, Khanna A, Feng J, Patel S, Zhang W, Gong Y, Huo L, Staerkel G. Analytical Performance of Cervista HPV 16/18 in SurePath Pap Specimens. Diagn Cytopathol 43(4):301-6, 2015. e-Pub 2014. PMID: 25352375.
12. Chen J, Lee HJ, Wu X, Huo L, Kim SJ, Xu L, Wang Y, He J, Reddy Bollu L, Gao G, Su F, Briggs J, Liu X, Melman T, Asara JM, Fidler IJ, Cantley LC, Locasale JW, Weihua Z. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Research 3(75):554-65, 2015. e-Pub 2015.
13. Zhang S, Huo L, Arribas E, Middleton LP. Adenomyoepithelioma of the breast with associated atypical lobular hyperplasia: a previously unrecognized association with management implications. Ann Diagn Pathol 19(1):20-3, 2015. e-Pub 2014. PMID: 25631879.
14. Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez-MacGregor M, Yi M, Hunt KK, Strom EA. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol 22(1):90-5, 2015. e-Pub 2014. PMID: 25249256.
15. Thaker NG, Hoffman KE, Stauder MC, Shaitelman SF, Strom EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pusztai L, Buchholz TA, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus 4:36, 2015. e-Pub 2015. PMID: 25674496.
16. Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu Y. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. Hum Pathol 45(9):1951-6, 2014. e-Pub 2014. PMID: 25074542.
17. Debeb BG, Gong Y, Atkinson RL, Sneige N, Huo L, Gonzalez-Angulo A, Hung MC, Valero V, Ueno NT, Woodward WA. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res 33(1), 2014. e-Pub 2014.
18. Gong Y, Wang J, Huo L, Wei W, Ueno NT, Woodward WA. Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. Clin Breast Cancer 14(3):e81-8, 2014. e-Pub 2013. PMID: 24461456.
19. Gong Y, Wei W, Wu Y, Ueno NT, Huo L. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. Cancer 120(12):1775-9, 2014. e-Pub 2014. PMID: 24634055.
20. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer 120(9):1319-28, 2014. e-Pub 2014. PMID: 24510381.
21. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol 25(5):1004-1011, 2014. e-Pub 2014.
22. Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L (corresponding author). Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer 13(6):439-49, 2013. e-Pub 2013. PMID: 24119786.
23. Zhao L, Gong Y, Wang J, Dawlett M, Huo L, Caraway NP, Guo M. Ultrasound-guided fine-needle aspiration biopsy of thyroid bed lesions from patients with thyroidectomy for thyroid carcinomas. Cancer Cytopathol 121(2):101-7, 2013. e-Pub 2012. PMID: 22605565.
24. Huo L (corresponding author), Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology 62(2):267-74, 2013. e-Pub 2012. PMID: 22963676.
25. Li X, Deavers MT, Guo M, Liu P, Gong Y, Albarracin CT, Middleton LP, Huo L (corresponding author). The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Mod Pathol 26(1):71-8, 2013. e-Pub 2012. PMID: 22899286.
26. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus 2:409, 2013. e-Pub 2013. PMID: 24156086.
27. Xiao Y, Lu L, Zhang A, Zhang Y, Sun L, Huo L, Li F.. Highly enhanced acetone sensing performances of porous and single crystalline ZnO nanosheets: high percentage of exposed (100) facets working together with surface modification with Pd nanoparticles. ACS Appl Mater Interfaces 4(8):3797-804, 2012. e-Pub 2012.
28. Xu J, Wan M, He Q, Bassett RL, Fu X, Chen AC, Shi F, Creighton CJ, Schiff R, Huo L (corresponding author), Liu D. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat 134(2):531-41, 2012. e-Pub 2012. PMID: 22576469.
29. Adejolu M, Huo L, Rohren E, Santiago L, Yang WT. False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol 198(3):W304-14, 2012. PMID: 22358030.
30. Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 131(1):41-8, 2012. e-Pub 2011. PMID: 21331622.
31. Blessing A, Xu L, Gao G, Bollu LR, Li H, Wu X, Ren J, Su F, Huang WC, Hung MC, Huo L, Palapattu GS, Weihua Z.. Sodium/glucose co-transporter 1 expression increases in human diseased prostate. J Cancer Sci Ther 4(9):306-12, 2012.
32. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117(24):5476-84, 2011. e-Pub 2011. PMID: 21713757.
33. McLemore MS, Huo L (co-first author), Deavers MT, Curry JL, Torres-Cabala CA, Wang WL, Prieto VG. Cutaneous epithelioid angiomatous nodule of the chest wall with expression of estrogen receptor: a mimic of carcinoma and a potential diagnostic pitfall. J Cutan Pathol 38(10):818-22, 2011. e-Pub 2011. PMID: 21752053.
34. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 42(8):1169-77, 2011. e-Pub 2011. PMID: 21334720.
35. Huo L (corresponding author). A practical approach to grossing breast specimens. Ann Diagn Pathol 15(4):291-301, 2011. PMID: 21745648.
36. Lee YS, Mathew J, Dogan BE, Resetkova E, Huo L, Yang WT. Imaging features of micropapillary DCIS: correlation with clinical and histopathological findings. Acad Radiol 18(7):797-803, 2011. e-Pub 2011. PMID: 21419669.
37. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology 59(1):106-15, 2011. PMID: 21668471.
38. Huo L (corresponding author), Bell D, Qiu H, Sahin A, Wu Y, Sneige N. Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma. Ann Diagn Pathol 15(2):84-92, 2011. e-Pub 2010. PMID: 21163678.
39. Brown AS, Hunt KK, Shen J,Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC, Ching CD, Gilcrease MZ. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116(12):2878-83, 2010. PMID: 20564394.
40. Huo L (corresponding author), Gilcrease MZ. Fibroepithelial lesions of the breast with pleomorphic stromal giant cells: a clinicopathologic study of 4 cases and review of the literature. Ann Diagn Pathol 13(4):226-32, 2009. e-Pub 2009. PMID: 19608080.
41. Nguyen CV, Deavers MT, Quinones J, Huo L (corresponding author). Estrogen receptor immunohistochemistry for confirmation of sentinel lymph node metastasis in cases with equivocal cytokeratin positivity. Appl Immunohistochem Mol Morphol 17(2):139-145, 2009. PMID: 19521277.
42. Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 107(8):1760-1768, 2006. PMID: 16977650.
43. Huo L, Moran CA, Fuller GN, Gladish G, Suster S. Pulmonary artery sarcoma: a clinicopathologic and immunohistochemical study of 12 cases. Am J Clin Pathol 125(3):419-424, 2006. PMID: 16613346.
44. Huo L, Lai S, Gladish G, Czerniak BA, Moran CA. Pulmonary artery angiosarcoma: a clinicopathologic and radiological correlation. Ann Diagn Pathol 9(4):209-214, 2005. PMID: 16084454.
45. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, Laskin WB, Yeldandi A, Teh BT, Yang XJ. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol 36(3):262-268, 2005. PMID: 15791570.
46. Gong Y, Sun X, Huo L, Wiley EL, Rao MS. Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in invasive micropapillary carcinoma of the breast. Histopathology 46(1):24-30, 2005. PMID: 15656882.
47. Patton KT, Tretiakova MS, Yao JL, Papavero V, Huo L, Adley BP, Wu G, Huang J, Pins MR, Teh BT, Yang XJ. Expression of RON proto-oncogene in renal oncocytoma and chromophobe renal cell carcinoma. Am J Surg Pathol 28(8):1045-50, 2004. PMID: 15252311.
48. Huo L, Scarpulla RC. Mitochondrial DNA instability and peri-implantation lethality associated with targeted disruption of nuclear respiratory factor 1 in mice. Mol Cell Biol 21(2):644-654, 2001. PMID: 11134350.
49. Huo L, Scarpulla RC. Multiple 5'-untranslated exons in the nuclear respiratory factor 1 gene span 47 kb and contribute to transcript heterogeneity and translational efficiency. Gene 233(1-2):213-224, 1999. PMID: 10375638.

Invited Articles

1. Huo L. Commentary on: Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. Breast Disease: A Year Book Quarterly 27(4):278-279, 2017.
2. Huo L. Commentary on: Androgen Receptor Expression in breast cancer in relation to molecular phenotype: Results from the Nurses’ Health Study. Breast Diseases: A Year Book Quarterly 23(2):155-156, 2012.
3. Huo L. Commentary on: Phenotypic Alterations in Ductal Carcinoma In Situ-associated Myoepithelial Cells: Biologic and Diagnostic Implications. Breast Diseases: A Year Book Quarterly 20(4):402-404, 2009.
4. Huo L. Commentary on: HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Breast Diseases: A Year Book Quarterly 18(1):66-67, 2007.

Abstracts

1. Ding Q, Wang Y, Zuo Z, Ueno N, Wei W, Huo L. Decreased expression of miR-26b in advanced breast cancer. The 105th Annual Meeting, United States and Canadian Academy of Pathology, 2016.
2. Li X, Krisnamurti U, Huo L, Peng L. Male breast carcinoma has worse prognosis than female breast carcinoma. The 105th Annual Meeting, United States and Canadian Academy of Pathology, 2016.
3. Chen H, Lu X, Singh R, Huo L, Bousamra A, Abraham R, Virani S, Mehrotra M, Mishra B, Roy-Chowdhuri S, Routbort M, Kenneth A, Broaddus R, Yao H, Sahin A, Patel KP, Luthra R. Quantitative assessment of ESR, PGR, and genome-wide copy number aberrations in advanced breast cancer by SNP Microarray. Association for Molecular Pathology 2015 Meeting, 2015.
4. Vila J, Mittendorf EA, Basset RL, Bedrosian I, Shaitelman SF, Stauder, MC, Chavez-McGregor M, Litton JF,Yang WT, Huo L, Kuerer HM, Hunt KK, Caudle AS. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast cancer patients. American Society of Clinical Oncology Meeting, 2015.
5. Chen H, Singh RR, Huo L, Lu X, Bousamra A, Abraham R, Mehrotra M, Mishra BM, Virani S, Roy-Chowdhuri S, Routbort M, Aldape K, Broaddus R, Sahin A, Patel KP, Luthra R. FGFR1 and EGFR amplification in breast cancer. The 104th Annual Meeting, United States and Canadian Academy of Pathology, 2015.
6. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Zhang XH, Calin GA, Krishnamurthy S, Ueno NT, Buchholz TA, Reuben JM, and Woodward WA. The microRNA miR-141 is a key regulator of brain metastasis from breast cancer. San Antonio Breast Cancer Symposium, 2014.
7. Anfossi S, Giordano A, Huo L, Alvarez RH, Valero V, Hortobagyi GN, Woodward WA, Ueno NT, Calin GA, Reuben JM. High miR-19a serum levels are prognostic of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer may derive from an effective antibody-dependent cell-mediated cytotoxicity induced by trastuzumab. San Antonio Breast Cancer Symposium, 2014.
8. Chen H, Broaddus R, Huo L, Zhang M, Guo C, Robinson M, Trivedi S, Fernandez R, Navai N, Lu X. Examination of HER2 overexpression and amplification in urothelial carcinoma with micropapillary features using ASCO/CAP 2013 guideline. Association for Molecular Pathology 2014 Meeting, 2014.
9. Debeb BG, Lacerda L, Anfossi A, Diagaradjane P, Chu K, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Zhang XH, Calin GA, Krishnamurthy S, Ueno NT, Buchholz TA, Reuben JM, and Woodward WA. The microRNA miR-141 is a key regulator of brain metastasis from breast cancer. Fourth Annual Brain Metastases Research and Emerging Therapy Conference, 2014.
10. Lee SM, Huo L, Lazar AJ, Wang WL. C-MYC expression in sporadic and radiation-associated sarcomas. The 102nd Annual Meeting, United States and Canadian Academy of Pathology, 2014.
11. Lee SM, Huo L, Lazar AJ, Wang WL. MYC expression in mammary vascular tumors. The 102nd Annual Meeting United States and Canadian Academy of Pathology, 2014.
12. Debeb BG, Lacerda L, Li L,Larson R, Xu W, Huo L, Wei C, Reuben JM, Ueno NT, Buchholz TA, Woodward WA. The miR-200 family as a potential therapeutic target in inflammatory breast cancer. AACR Annual Meeting, 2013.
13. Gong Y, Wei W, Wu Y, Huo L. Expression of androgen receptor in triple-negative breast carcinomas and inflammatory breast carcinomas. The 102nd Annual Meeting, United States and Canadian Academy of Pathology, 2013.
14. Li X, Huo L, Moulder SL, Gilcrease MZ. Analysis of gene mutations in subtypes of metaplastic carcinoma of the breast. The 102nd Annual Meeting, United States and Canadian Academy of Pathology, 2013.
15. Yi M, Huo L, Koenig K, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Symmans WF, Crow JR, Shah RR, Hortobagyi GN, Hunt KK. Estrogen receptor positivity: 10% or 1%?. San Antonio Breast Cancer Symposium, 2012.
16. Debeb BG, Lacerda L, Larson R, Li L, Xu W, Huo L, Wei C, Krishnamurthy S, Reuben JM, Ueno NT, Buchholz TA, Woodward WA. The miR-200 family as a potential therapeutic target in inflammatory breast cancer. 3rd International Inflammatory Breast Cancer (IBC) meeting, 2012.
17. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN Woodward WA, Alvarez RH, Lucci A, Bedrosian I, Kuerer HM, Hunt K, Huo L, Babiera G. Primary tumor resection to improve survival and local disease control in stage IV inflammatory breast cancer. American Society of Clinical Oncology Annual Meeting, 2012.
18. Alvarez R, Cristofanilli M, Ensor J, Lucci A, Yang WT, Le-Petross HT, Reuben JM, Babiera G, Huo L, Gong Y, Woodward WA, Parker CA, Willey JS, Buchholz TA, Ueno MT, Valero V. Limited efficacy and significant toxicities of lapatinib (Lap) plus chemotherapy as neoadjuvant therapy (NAC) for HER2-positive inflammatory breast cancer (IBC) patients (Pts). American Society of Clinical Oncology Annual Meeting, 2012.
19. Li X, Deavers MT, Guo M, Middleton L, Liu P, Huo L. The effect of prolonged cold ischemia time on estrogen receptor detection in breast cancer. The 101st Annual Meeting, United States and Canadian Academy of Pathology, 2012.
20. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Zhang XH, Calin GA, Krishnamurthy S, Ueno NT, Buchholz TA, Reuben JM, and Woodward WA. The microRNA miR-141 is a key regulator of brain metastasis from breast cancer. 2014 San Antonio Breast Cancer Symposium, 2011.
21. Nayak A, Gilcrease MZ, Middleton LP, Carkaci S, Zhang J, Sneige N, Huo L.. Papillomas on core needle biopsy: analysis of 88 cases. The 100th Annual Meeting, United States and Canadian Academy of Pathology, 2011.
22. Lane D, Arribas E, Resetkova E, Huo L, Yang W. The significance of residual mammographic calcifications after neoadjuvant therapy. The RSNA 96th Scientific Assembly and Annual Meeting, 2010.
23. Wei B, Tian Z, Tang F, Wei W, Milcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton LP, Sahin A, Chen J, Abraham SC. Prognostic factors of primary invasive mammary neuroendocrine carcinoma: clinicopathologic analsis of 74 cases. The 99th Annual Meeting, United States and Canadian Academy of Pathology, 2010.
24. Lester TR, Arun BK, Gutierrez Barrera A, Huo L, Albarracin CT, Gilcrease MZ. Triple-negative phenotype and/or high mitotic rate may improve selection of high-risk patients for BRCA testing. The 99th Annual Meeting, United States and Canadian Academy of Pathology, 2010.
25. Gong Y, Huo L, Sneige N, Cristofanilli M. Positive expression of enhancer of zeste homolog 2 (EZH2) predicts shorter overall survival in patients with inflammatory breast cancer. The 99th Annual Meeting, United States and Canadian Academy of Pathology, 2010.
26. Huo L. Correlation of apocrine DCIS on core needle biopsy with excision. The 99th Annual Meeting, United States and Canadian Academy of Pathology, 2010.
27. Nguyen CV, Deavers MT, Quinones J, Huo L. Estrogen receptor immunohistochemistry for confirmation of sentinel lymph node metastasis in cases with equivocal cytokeratin positivity. The 97th annual meeting, United States and Canadian Academy of Pathology, 2008.
28. Tang F, Gilcrease MZ, Albarracin CT, Huo L, Middleton LP, Resetkova E, Wu Y. Invasive solid papillary carcinoma of the breast: a clinicopathologic analysis of 52 cases. The 97th Annual Meeting, United States and Canadian Academy of Pathology, 2008.
29. Huo L, Resetkova E, Lopez A, Sneige N. Sentinel lymph node (SLN) sampling in patients with core biopsy diagnosis of ductal carcinoma in situ (DCIS): UT M.D. Anderson cancer caner experience and future recommendations. The 95th annual meeting, United States and Canadian Academy of Pathology, 2006.
30. Huo L, Wu Y, Meric-Bernstam F, Sahin AA. Morphologic features of ipsilateral recurrent breast cancers in patients treated with breast conserving therapy (BCT). The 94th annual meeting, United States and Canadian Academy of Pathology, 2005.
31. Huo L, Patton KT, Adley BP, Gupta R, Papavero V, Laskin WB, Yeldandi A, Yang XJ. Anylysis of c-kit expression in 171 renal neoplasms. The 93rd Annual Meeting, United States and Canadian Academy of Pathology, 2004.
32. Huo L, Adley BP, Patton KT, Sugimura J, Teh BT, Yang XJ. Comparison of c-kit expression in chromophobe renal cell carcinoma and renal oncocytoma. The 93rd Annual Meeting, United States and Canadian Academy of Pathology, 2004.
33. Diaz LK, Huo L, Gupta A, Kidwai N, Sneige N, Wiley EL. Comparison of the effects of alcoholic formalin fixation to standard formalin fixationon estrogen receptor analysis by immunohistochemistry in breast cancer. The 93rd Annual Meeting, United States and Canadian Academy of Pathology, 2004.
34. Huo L, Kashireddy P, Rao MS, Diaz LK. Peroxisome proliferator-activacted receptor gamma expression in invasive breast cancer. The 93rd Annual Meeting, United States and Canadian Academy of Pathology, 2004.
35. Diaz LK, Huo L, Herm J, Clatch R. Rapid and low cost image analysis for tissue microarray immunohistochemistry. The 93rd Annual Meeting, United States and Canadian Academy of Pathology, 2004.
36. Chuang ST, Gupta A, Huo L, Keh P, Rao MS.. Comparative analysis of cell cycle regulatory proteins and cell adhesion molecules in endometrioid adenocarcinomas and serous papillary carcinomas of the ovary. The 92nd Annual Meeting, United States and Canadian Academy of Pathology, 2003.

Book Chapters

1. Huo L, Albarracin CT, Sneige N. Immunological and Molecular Studies in Breast Tumors. In: Immunological and Molecular Diagnosis of Cancer. Nova Science Publishers: San Juan Capistrano, CA, 209-244, 2011.

Letters to the Editor

1. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity?. Arch Pathol Lab Med 134: 162-3; author reply 163, 2010.